First Allied Advisory Services’s Orexigen Therapeutics, Inc. OREX Stock Holding History

First Allied Advisory Services’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,660	Closed	-$11K	–	1142
2016 Q2	$11K	Sell	2,660 -45	-2%	-$203	﹤0.01%	1030
2016 Q1	$13K	Sell	2,705 -891	-25%	-$11.6K	﹤0.01%	998
2015 Q4	$59K	Sell	3,596 -1,089	-23%	-$26K	﹤0.01%	1070
2015 Q3	$99K	Buy	4,685 +629	+16%	+$21.6K	0.01%	1003
2015 Q2	$200K	Buy	4,056 +166	+4%	+$9.92K	0.01%	1029
2015 Q1	$306K	Buy	+3,890	New	+$241K	0.02%	769

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

First Allied Advisory Services's OREX Position: Q3 2016 in Review

First Allied Advisory Services sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 2,660 shares — an estimated $11K sold.

First Allied Advisory Services first reported a position in OREX in Q1 2015 and held it in 6 quarters. The position peaked at $306K in Q1 2015. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

First Allied Advisory Services reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
First Allied Advisory Services sold 2,660 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $11K.
First Allied Advisory Services first reported a position in Orexigen Therapeutics, Inc. in Q1 2015 and held it in 6 quarters.
First Allied Advisory Services's Orexigen Therapeutics, Inc. position peaked at $306K in Q1 2015.
55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on First Allied Advisory Services's 13F filing for Q3 2016, filed 14 Nov 2016.